Keywords: biogen, third-quarter, income, falls, avonex, fails, match

Biogen's third-quarter income falls 24% as Avonex fails to match expectations

Article | 05 November 2007

The weaker-than-expected performance of the multiple sclerosis product Avonex (interferon beta-1a) led third quarter income at US biotechnology firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biogen Idec

Go to company listing

Related Drugs

Avonex

Interferon beta-1a

Natalizumab

Tysabri

Rebif

Go to drug listing